Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

Journal of Hepatology

Volumn 30, Issue 5, 1999, Pages 749-754

  Günther, Stephan ^a,b   Breunig, Franziska Von ^a   Santantonio, Teresa ^c   Jung, Maria Christina ^d   Gaeta, Giovanni B ^e   Fischer, Lutz ^f   Sterneck, Martina ^f   Will, Hans ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c UNIVERSITY OF BARI   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antiviral therapy; Famciclovir; Hepatitis B virus; Lamivudine; Mutation; Viral polymerase

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS ENZYME;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT FAILURE;

EID: 0033027088     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80124-X     Document Type: Article

References (34)

1. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol. 64:1990;613-620.
2. Lanford RE, Notvall L, Lee H, Beames B. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J Virol. 71:1997;2996-3004.
3. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol. 68:1994;6-13.
4. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:1989;3867-3874.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
6. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 348:1996;1212-1215.
7. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 125:1996;705-712.
8. Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol. 28:1998;359-368.
9. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation. 63:1997;1415-1419.
10. Klein M, Geoghegan J, Schmidt K, Böckler D, Korn K, Wittekind C, et al. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Transplantation. 64:1997;162-163.
11. Haller GW, Bechstein WO, Neuhaus R, Raakow R, Berg T, Hopf U, et al. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Transpl Int. 9:(Suppl. 1):1996;S210-S212.
12. Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg. 2:1996;253-262.
13. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat. 3:1996;211-215.
14. Böker KH, Ringe B, Krüger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation. 57:1994;1706-1708.
15. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother. 40:1996;1282-1284.
16. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
17. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 88:1991;8495-8499.
18. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 38:1994;719-723.
19. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:1997;216-225.
20. Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)- beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 39:1995;1430-1435.
21. Dannaoui E, Trépo C, Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antiviral Chem Chemother. 8:1997;38-46.
22. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 36:1992;2747-2757.
23. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 27:1998;1670-1677.
24. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol. 26:1997;1393-1395.
25. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
26. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
27. Ling R, Mutimer D, Ahmed N, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
28. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis. 177:1998;1382-1385.
29. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol. 55:1998;1567-1572.
30. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′,3′-dideoxy-3′- thiacytidine] in vitro. Antimicrob Agents Chemother. 40:1996;1957-1960.
31. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1157-1158.
32. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 27:1998;628-633.
33. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother. 4:1993;67-84.
34. Pichoud C, Seigneres B, Wang Z, Trépo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 29:1999;230-237.